Literature DB >> 8388199

Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.

T Yoshida1, S Mitsuhashi.   

Abstract

The in vitro antibacterial activity of NM394 was compared with those of other new quinolones. NM394 showed potent and broad-spectrum antibacterial activity against 2,606 recent clinical isolates. The activity of NM394 against gram-positive bacteria was 2- to 16-fold less than that of tosulfoxacin and sparfloxacin but was comparable to that of ofloxacin. Only against Streptococcus pyogenes was the activity of NM394 equal to that of sparfloxacin. Against gram-negative bacteria, NM394 showed antibacterial activity equal to that of ciprofloxacin. Against quinolone-resistant Pseudomonas aeruginosa (norfloxacin MIC, > 6.25 micrograms/ml), the activity of NM394 was greater than those of the other agents tested. NM394 was rapidly bactericidal at concentrations near the MIC. NM394 inhibited supercoiling activities of DNA gyrase purified from Staphylococcus aureus, Escherichia coli, and P. aeruginosa; the 50% inhibitory concentrations were 18.0, 0.41, and 2.05 micrograms/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388199      PMCID: PMC187765          DOI: 10.1128/AAC.37.4.793

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Drug resistance of Pseudomonas aeruginosa with special reference to new quinolones.

Authors:  S Iyobe; K Hirai; H Hashimoto
Journal:  Antibiot Chemother (1971)       Date:  1991

2.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

3.  Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant.

Authors:  Y Inoue; K Sato; T Fujii; K Hirai; M Inoue; S Iyobe; S Mitsuhashi
Journal:  J Bacteriol       Date:  1987-05       Impact factor: 3.490

4.  Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.

Authors:  K Sato; Y Inoue; T Fujii; H Aoyama; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

5.  In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.

Authors:  K Fujimaki; T Noumi; I Saikawa; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa.

Authors:  H Yoshida; M Nakamura; M Bogaki; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 8.  Bacterial resistance to fluoroquinolones.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa.

Authors:  E B Jakics; S Iyobe; K Hirai; H Fukuda; H Hashimoto
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

View more
  7 in total

1.  In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.

Authors:  M P Montanari; M Mingoia; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.

Authors:  G Prats; C Roig; E Miró; F Navarro; B Mirelis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-04-19       Impact factor: 3.267

3.  Prulifloxacin.

Authors:  Susan J Keam; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Quinolone activity against anaerobes: microbiological aspects.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 5.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Prophylactic single-dose prulifloxacin for catheter-associated urinary tract infection after tension-free vaginal tape procedure.

Authors:  Fabio Ghezzi; Maurizio Serati; Antonella Cromi; Stefano Uccella; Stefano Salvatore; Pierfrancesco Bolis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-11-21

Review 7.  Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis.

Authors:  Francesco Blasi; Stefano Aliberti; Paolo Tarsia; PierAchille Santus; Stefano Centanni; Luigi Allegra
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.